These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 25037971)

  • 1. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
    Marthey L; Sa-Cunha A; Blanc JF; Gauthier M; Cueff A; Francois E; Trouilloud I; Malka D; Bachet JB; Coriat R; Terrebonne E; De La Fouchardière C; Manfredi S; Solub D; Lécaille C; Thirot Bidault A; Carbonnel F; Taieb J
    Ann Surg Oncol; 2015 Jan; 22(1):295-301. PubMed ID: 25037971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
    Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T
    Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
    Suker M; Beumer BR; Sadot E; Marthey L; Faris JE; Mellon EA; El-Rayes BF; Wang-Gillam A; Lacy J; Hosein PJ; Moorcraft SY; Conroy T; Hohla F; Allen P; Taieb J; Hong TS; Shridhar R; Chau I; van Eijck CH; Koerkamp BG
    Lancet Oncol; 2016 Jun; 17(6):801-810. PubMed ID: 27160474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
    Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
    N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
    Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
    Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
    Kozuch P; Grossbard ML; Barzdins A; Araneo M; Robin A; Frager D; Homel P; Marino J; DeGregorio P; Bruckner HW
    Oncologist; 2001; 6(6):488-95. PubMed ID: 11743211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
    Trouilloud I; Dupont-Gossard AC; Malka D; Artru P; Gauthier M; Lecomte T; Aparicio T; Thirot-Bidault A; Lobry C; Asnacios A; Manet-Lacombe S; Fein F; Dubreuil O; Landi B; Zaanan A; Bonnetain F; Taïeb J
    Eur J Cancer; 2014 Dec; 50(18):3116-24. PubMed ID: 25454414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
    Orlandi A; Calegari MA; Martini M; Cocomazzi A; Bagalà C; Indellicati G; Zurlo V; Basso M; Cassano A; Larocca LM; Barone C
    Clin Transl Oncol; 2016 Oct; 18(10):988-95. PubMed ID: 26742940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
    Lorgis V; Chauffert B; Gentil J; Ghiringhelli F
    Anticancer Res; 2012 Sep; 32(9):4125-30. PubMed ID: 22993372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
    Lee MG; Lee SH; Lee SJ; Lee YS; Hwang JH; Ryu JK; Kim YT; Kim DU; Woo SM
    Chemotherapy; 2013; 59(4):273-9. PubMed ID: 24457620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
    Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
    J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    Stein SM; James ES; Deng Y; Cong X; Kortmansky JS; Li J; Staugaard C; Indukala D; Boustani AM; Patel V; Cha CH; Salem RR; Chang B; Hochster HS; Lacy J
    Br J Cancer; 2016 Mar; 114(7):737-43. PubMed ID: 27022826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
    Portal A; Pernot S; Tougeron D; Arbaud C; Bidault AT; de la Fouchardière C; Hammel P; Lecomte T; Dréanic J; Coriat R; Bachet JB; Dubreuil O; Marthey L; Dahan L; Tchoundjeu B; Locher C; Lepère C; Bonnetain F; Taieb J
    Br J Cancer; 2015 Sep; 113(7):989-95. PubMed ID: 26372701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
    Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
    J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
    Umemura A; Nitta H; Sasaki A; Takahara T; Hasegawa Y; Wakabayashi G
    Hepatogastroenterology; 2014 May; 61(131):814-20. PubMed ID: 26176079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.